公开(公告)号：US20230174532A1

公开(公告)日：2023-06-08

申请号：US18162052

申请日：2023-01-31

Applicant: Pfizer Inc.

Inventor： Christopher Ryan BUTLER ,  Michelle Renee GARNSEY ,  Kevin Alexander OGILVIE ,  Jana POLIVKOVA ,  Matthew Forrest SAMMONS ,  Aaron Christopher SMITH ,  Qingyi Yang

IPC: C07D471/20 ,  C07D519/00

CPC classification number: C07D471/20 ,  C07D519/00 ,  C07B2200/13

Abstract: Described herein are methods of treating MC4R-related conditions, diseases, or disorders by administering compounds of Formula I:




or their pharmaceutically acceptable salts, wherein R1, R2, R3, X1, Y1, Y2, Y3, Y4 and Y5 are defined herein. Such conditions, diseases, or disorders include cachexia, anorexia, or anorexia nervosa.

公开(公告)号：US20250084084A1

公开(公告)日：2025-03-13

申请号：US18954736

申请日：2024-11-21

Applicant: Pfizer Inc.

Inventor： Christopher Ryan BUTLER ,  Michelle Renee GARNSEY ,  Kevin Alexander OGILVIE ,  Jana POLIVKOVA ,  Matthew Forrest SAMMONS ,  Aaron Christopher SMITH ,  Qingyi Yang

IPC: C07D471/20 ,  C07D519/00

Abstract: Described herein is a crystalline form of (2R)-2-(5-fluoro-2-methoxypyridin-4-yl)-1-[(2S)-7-methyl-6-(pyrimidin-2-yl)-3,4-dihydro-1H-spiro[1,8-naphthyridine-2,3-pyrrolidin]-1-yl]propan-1-one having a powder X-ray diffraction pattern comprising at least one characteristic peak, in terms of 2θ at a copper wavelength, selected from 8.7±0.2, 11.1±0.2, and 13.3±0.2.